Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Japanese Encephalitis purified inactivated vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| IC51 Batch A | ACTIVE_COMPARATOR | - |
| IC51 Batch B | ACTIVE_COMPARATOR | - |
| IC51 Batch C | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Japanese Encephalitis purified inactivated vaccine | BIOLOGICAL | IC51 6 mcg i.m. injection on Day 0 and Day 28 |
Main Inclusion Criteria: * Male and female healthy adults aged at least 18 years, with written informed consent and either no childbearing potential or negative pregnancy test Main Exclusion Criteria: * History of immunodeficiency or immunosuppressive therapy, * Known Human Immunodeficiency Virus...
Japanese Encephalitis purified inactivated vaccine is used for the prevention of Japanese Encephalitis, a viral infection transmitted by mosquitoes that can cause inflammation of the brain. It is an investigational vaccine intended to protect individuals aged 18 years and older from this disease.
Japanese Encephalitis purified inactivated vaccine is being developed by Valneva SE, a biopharmaceutical company. Valneva's stock is traded under the ticker symbol VALN. The vaccine is currently in clinical development for the prevention of Japanese Encephalitis.
Japanese Encephalitis purified inactivated vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not been approved by regulatory authorities. The Phase 3 trial has been completed, and the vaccine remains under evaluation for its intended use in preventing Japanese Encephalitis.
Japanese Encephalitis purified inactivated vaccine has been studied in one completed Phase 3 clinical trial, identified as NCT00595465. This trial compared three commercial batches of the vaccine in 389 healthy adult volunteers aged 18 years and older, conducted in Austria and Germany.
Yes, Japanese Encephalitis purified inactivated vaccine is also known as IC51. The Phase 3 clinical trial NCT00595465 is titled 'Comparison of Three Commercial Batches of the Japanese Encephalitis Vaccine IC51,' confirming that IC51 is an alternative name for this vaccine.